Equities analysts expect West Pharmaceutical Services, Inc. (NYSE:WST) to report earnings per share (EPS) of $1.74 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for West Pharmaceutical Services’ earnings, with the lowest EPS estimate coming in at $1.68 and the highest estimate coming in at $1.85. West Pharmaceutical Services reported earnings per share of $1.25 in the same quarter last year, which would indicate a positive year-over-year growth rate of 39.2%. The business is scheduled to announce its next quarterly earnings report on Thursday, July 22nd.
According to Zacks, analysts expect that West Pharmaceutical Services will report full year earnings of $6.79 per share for the current financial year, with EPS estimates ranging from $6.10 to $7.40. For the next fiscal year, analysts forecast that the company will post earnings of $7.42 per share, with EPS estimates ranging from $6.76 to $8.00. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 29th. The medical instruments supplier reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.63. West Pharmaceutical Services had a net margin of 14.69% and a return on equity of 19.01%.
Separately, Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $355.00 price target on the stock in a research note on Wednesday, April 21st.
WST traded down $0.70 during trading on Thursday, hitting $329.18. The stock had a trading volume of 11,987 shares, compared to its average volume of 464,733. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.23 and a current ratio of 2.96. The firm has a market capitalization of $24.31 billion, a P/E ratio of 87.04, a PEG ratio of 3.86 and a beta of 1.13. The company’s 50-day moving average price is $297.49 and its 200 day moving average price is $287.48. West Pharmaceutical Services has a twelve month low of $186.82 and a twelve month high of $334.83.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 5th. Stockholders of record on Wednesday, April 21st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, April 20th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.21%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.99%.
Several large investors have recently bought and sold shares of WST. Norges Bank acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth $211,338,000. BlackRock Inc. grew its stake in West Pharmaceutical Services by 5.1% in the 4th quarter. BlackRock Inc. now owns 7,290,940 shares of the medical instruments supplier’s stock valued at $2,065,597,000 after acquiring an additional 350,911 shares during the last quarter. WCM Investment Management LLC grew its stake in West Pharmaceutical Services by 17.5% in the 4th quarter. WCM Investment Management LLC now owns 1,613,372 shares of the medical instruments supplier’s stock valued at $457,084,000 after acquiring an additional 240,412 shares during the last quarter. Brown Advisory Inc. grew its stake in West Pharmaceutical Services by 20.2% in the 4th quarter. Brown Advisory Inc. now owns 1,172,468 shares of the medical instruments supplier’s stock valued at $332,172,000 after acquiring an additional 196,946 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in West Pharmaceutical Services by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,624,247 shares of the medical instruments supplier’s stock valued at $1,310,095,000 after acquiring an additional 175,527 shares during the last quarter. 92.55% of the stock is currently owned by institutional investors and hedge funds.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com